Reference : Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized contr...
Scientific journals : Article
Human health sciences : General & internal medicine
http://hdl.handle.net/2268/103712
Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate.
English
Sambrook, P. N. [> > > >]
Roux, C. [> > > >]
Devogelaer, J. P. [> > > >]
Saag, K. [> > > >]
Lau, C. S. [> > > >]
Reginster, Jean-Yves mailto [Université de Liège - ULg > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé]
Bucci-Rechtweg, C. [> > > >]
Su, G. [> > > >]
Reid, D. M. [> > > >]
2012
BONE
Elsevier Science
50
289-295
Yes (verified by ORBi)
International
8756-3282
1873-2763
New York
NY
[en] BACKGROUND: We studied 265 men (mean age 56.4years; range 18-83years), among patients enrolled in two arms of a double-blind, 1-year study comparing the effects of zoledronic acid (ZOL) with risedronate (RIS) in patients either commencing (prednisolone 7.5mg/day or equivalent) (prevention arm, n=88) or continuing glucocorticoid therapy (treatment arm, n=177). METHODS: Patients received either a single ZOL 5mg infusion or RIS 5mg oral daily at randomization, along with calcium (1000mg) and vitamin D (400-1200IU). Primary endpoint: difference in percentage change from baseline in bone mineral density (BMD) at the lumbar spine (LS) at 12months. Secondary endpoints: percentage changes in BMD at total hip (TH) and femoral neck (FN), relative changes in bone turnover markers (beta-CTx and P1NP), and overall safety. FINDINGS: In the treatment subpopulation, ZOL increased LS BMD by 4.7% vs. 3.3% for RIS and at TH the percentage changes were 1.8% vs. 0.2%, respectively. In the prevention subpopulation, bone loss was prevented by both treatments. At LS the percentage changes were 2.5% vs. -0.2% for ZOL vs. RIS and at TH the percentage changes were 1.1% vs. -0.4%, respectively. ZOL significantly increased lumbar spine BMD more than RIS at Month 12 in both the prevention population (p=0.0024) and the treatment subpopulation (p=0.0232) in men. In the treatment subpopulation, ZOL demonstrated a significantly greater reduction in serum beta-CTx and P1NP relative to RIS at all time-points. In the prevention subpopulation, ZOL significantly reduced beta-CTx at all time-points, and P1NP at Month 3 (p=0.0297) only. Both treatments were well tolerated in men, albeit with a higher incidence of influenza-like illness and pyrexia events post-infusion with ZOL. INTERPRETATION: Once-yearly ZOL preserves or increases BMD within 1year to a greater extent than daily RIS in men receiving glucocorticoid therapy.
http://hdl.handle.net/2268/103712
10.1016/j.bone.2011.10.024
Copyright A(c) 2011. Published by Elsevier Inc.

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Restricted access
Bisphosphonates and glucocorticoid osteoporosis in men results of a randomized controlled trial comparing zoledronic acid with risedronate.pdfPublisher postprint498.54 kBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.